- Smarter Solid State Research via Prediction and Simulation
- Physical Property Based Crystallization Process Development
- Particle Engineering and DS-DP Co-Processing
- Partnering for Addressing Challenges of Today and the Future
Crystallization technologies are bridges between drug substance molecules (DS) and drug products (DP) enabling consistent and robust safety and efficacy profiles of small molecule based medicines. In an effort to fully utilize existing tools and develop better new methodologies for solving bottleneck problems in new drug development, the Center for Pharma Crystallization (CfPC) at J-Star Research launches its first annual conference, jointly with XtalPi, as a service to the pharmaceutical industry.
As we ascend the scale of scrutiny of a drug substance, it starts at the molecular level with single crystal structures each with distinct physicochemical as well as mechanical properties. Discovery of new crystalline solids, pre-formulation evaluation of lead solid forms, development of robust and efficient crystallization processes, and engineering of DS particles with desired formulation properties all can be accelerated with deeper fundamental understanding and enhanced application of existing and new technologies.
Considering the impact of the Covid-19 outbreak, this year’s Summit will be held online (live). This provides the advantage of allowing more attendees than a normal face-to-face meeting. The registration for invited attendees starts in June, and the registration for the general public starts on August 7th, 2020.